Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
25. April 2023 16:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Repayment of Convertible Notes
03. April 2023 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Two Upcoming Investor Conferences
08. März 2023 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Cowen 43rd Annual Health Care Conference
01. März 2023 16:55 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
28. Februar 2023 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021Fourth quarter 2022 Qelbree® net product sales of $23.6 million increased 29% compared to third quarter of...
Supernus Enters Into $150 Million Credit Facility
14. Februar 2023 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
09. Februar 2023 18:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
22. November 2022 17:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at Two November Healthcare Conferences
08. November 2022 17:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Third Quarter 2022 Financial Results
08. November 2022 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million...